Radioiodine remnant ablation in differentiated thyroid cancer after combined endogenous and exogenous TSH stimulation

被引:8
|
作者
Vrachimis, A. [1 ]
Schober, O. [1 ]
Riemann, B. [1 ]
机构
[1] Univ Hosp Muenster, Dept Nucl Med, Munster, Germany
来源
NUKLEARMEDIZIN-NUCLEAR MEDICINE | 2012年 / 51卷 / 03期
关键词
Radioiodine; remnant ablation; thyroid hormone withdrawal; rhTSH; RECOMBINANT HUMAN THYROTROPIN; HORMONE WITHDRAWAL; FOLLOW-UP; CARCINOMA; THERAPY; HYPOTHYROIDISM; RISK; MANAGEMENT; RHTSH; COST;
D O I
10.3413/Nukmed-0432-11-10
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
Aim: Radioiodine remnant ablation (RRA) after (near-)total thyroidectomy (TE) is a key element in patients with differentiated thyroid cancer (DTC). The use of exogenous TSH stimulation (rhTSH) prior to RRA has shown promising results as compared to conventional thyroid hormone withdrawal (THW). As yet, the efficacy of RRA after brief THW and single rhTSH administration has not been assessed. Patients, methods: The study sample comprised 147 patients with DTC referred to our center between May 2008 and September 2010. All patients received TE with subsequent RRA. None of these 147 patients had evidence of distant metastasis. 93 patients had endogenous TSH stimulation 4-5 weeks after surgery (group I) and twenty-six received two rhTSH injections (group II). 28 patients were treated with a single rhTSH injection after a brief THW (group III). RRA-Efficacy was assessed three months after therapy by diagnostic whole-body scan and measurement of the tumour marker thyroglobulin (Tg) under TSH stimulation. Results: Three categories of success were defined for remnant ablation. Based on the definition of successful remnant ablation no visible uptake and a Tg <= 2.0 ng/ml (category 1) was seen in 62/93 patients in group I, in 17/26 patients in group II (p = n.s.) and in 12/28 patients in group III (p < 0.05). Visible radioiodine uptake and a Tg <= 2.0 ng/ml (category 2) was seen in 16/28 patients of group III and thus significantly more frequent than in group I (28/93 patients) (p < 0.01). However, patients in group III (16/28 patients) and group II (8/26 patients) showed no significant difference in this category (p = n.s.). Visible radioiodine uptake and a Tg > 2.0 ng/ml (category 3) was found in 3/93 patients in group I and 1/26 patients in group II but in no patient in group III. Conclusion:The third strategy of remnant ablation using a single injection of rhTSH after a brief THW period resulted in a significant higher rate of patients with residual uptake in the thyroid bed and a Tg level below 2 ng/ml three months after remnant ablation in comparison to THW. However, the overall efficacy of the third protocol was not significantly different as compared to two rhTSH injections. Under the aspect of the supply shortage of rhTSH the combined endogenous and exogenous TSH stimulation may be an attractive alternative for remnant ablation in differentiated thyroid cancer.
引用
收藏
页码:67 / 72
页数:6
相关论文
共 50 条
  • [41] Radioiodine ablation and therapy in differentiated thyroid cancer under stimulation with recombinant human thyroid-stimulating hormone
    G. Berg
    G. Lindstedt
    M. Suurküla
    S. Jansson
    Journal of Endocrinological Investigation, 2002, 25 : 44 - 52
  • [42] Indication for radioiodine remnant ablation in differentiated thyroid cancer patients: does 2018 Italian consensus change anything?
    R. Forleo
    N. Fralassi
    F. Maino
    M. Capezzone
    L. Brilli
    T. Pilli
    S. Cantara
    M. G. Castagna
    Journal of Endocrinological Investigation, 2021, 44 : 139 - 144
  • [43] Efficacy of Low and High dose Of Radioiodine For The Ablation Of Thyroid Remnant In Patients With Differentiated Thyroid Cancer Coexisting Chronic Lymphocytic Thyroiditis
    Chao, M.
    Xie, J.
    Lv, Z.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2019, 46 (SUPPL 1) : S659 - S660
  • [44] Clinical and Demographic Characteristics of Tearing in Patients after Radioiodine Ablation for Differentiated Thyroid Cancer
    Yartsev, Vasily D.
    Solodkiy, Vladimir A.
    Fomin, Dmitriy K.
    Borisenko, Tatiana E.
    Atkova, Eugenia L.
    CURRENT EYE RESEARCH, 2021, 46 (09) : 1320 - 1324
  • [45] Thyroglobulin levels measured at the time of remnant ablation to predict response to treatment in differentiated thyroid cancer after thyroid hormone withdrawal or recombinant human TSH
    Fabian Pitoia
    Erika Abelleira
    Graciela Cross
    Endocrine, 2017, 55 : 200 - 208
  • [46] Thyroglobulin levels measured at the time of remnant ablation to predict response to treatment in differentiated thyroid cancer after thyroid hormone withdrawal or recombinant human TSH
    Pitoia, Fabian
    Abelleira, Erika
    Cross, Graciela
    ENDOCRINE, 2017, 55 (01) : 209 - 217
  • [47] Scintigraphic evaluation of salivary gland function in thyroid cancer patients after radioiodine remnant ablation
    Krcalova, Eva
    Horacek, Jiri
    Gabalec, Filip
    Zak, Pavel
    Dolezal, Jiri
    EUROPEAN JOURNAL OF ORAL SCIENCES, 2020, 128 (03) : 204 - 210
  • [48] Radioiodine therapy of goiter with low radioiodine uptake after endogenous TSH stimulation by antithyroid drugs
    Auffret, H.
    Cottereau, A.
    Paepegaey, A.
    Bienvenu, M.
    Mouraeff, Y.
    Benmihoub, I.
    Clerc, J.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2018, 45 : S115 - S116
  • [49] Long-term recurrence of thyroid cancer after thyroid remnant ablation with 1.1 and 3.7 GBq radioiodine
    Rosario, Pedro W. S.
    Purisch, Saulo
    Vasconcelos, Flavio P. J.
    Padrao, Eduardo L.
    Rezende, Leonardo L.
    Barroso, Alvaro L.
    NUCLEAR MEDICINE COMMUNICATIONS, 2007, 28 (06) : 507 - 508
  • [50] Diagnosis of poorly differentiated thyroid cancer with radioiodine scanning after thyrotropin alfa stimulation
    Juweid, Malik
    O'Dorisio, Thomas
    Milhem, Mohammed
    NEW ENGLAND JOURNAL OF MEDICINE, 2008, 359 (12): : 1295 - 1297